Industry Newsglp 1rdiabetesascletisclinical trial
Ascletis Doses First Participants With ASC30
4.0
Ascletis has dosed first participants in a 13-week U.S. Phase II study of ASC30, an oral small-molecule GLP-1R agonist for diabetes; topline data are expected in the third quarter of 2026.
Key Points
- 1Ascletis doses first participants in a 13-week U.S. Phase II trial
- 2Tests an oral small-molecule GLP-1R agonist, ASC30, as a diabetes treatment
- 3Topline efficacy and safety data are expected in the third quarter of 2026
Scoring Rationale
Progression to Phase II indicates moderate industry relevance, but RSS-only release provides limited details and constrains impact assessment.
Sources
Public references used for this report.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
250 free problems · No credit card
See all Health & Insurance problems
